A Nature Communications 2026 trial explores whether combining low-dose baricitinib with danazol can improve outcomes for primary immune thrombocytopenia (ITP). The strategy is built around two mechanistically distinct drugs, aiming to improve platelet stability in a setting where bleeding risk and treatment variability remain major clinical challenges. The report frames the study as a combination approach rather than a single-agent dose escalation, reflecting ongoing interest in improving efficacy while potentially managing tolerability. Trial outcomes will be the key determinant of whether this pairing earns a place in future ITP treatment algorithms.